基本信息 产品详情 公司简介 推荐产品
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
网站主页 化工产品目录 生物化工 抗体 一抗 多抗 IL7抗体 IL7抗体
  • IL7抗体—艾普蒂
  • IL7抗体—艾普蒂
  • IL7抗体—艾普蒂

1/3

IL7抗体—艾普蒂

Rabbit Polyclonal IL7 Antibody
询价 20μl 起订
50μl 起订
100μl 起订
上海 更新日期：2025-05-18

上海切尔齐生物科技有限公司

非会员
联系人：周***
电话：027***
手机：180***
邮箱：rui***

产品详情:

中文名称：
IL7抗体
英文名称：
Rabbit Polyclonal IL7 Antibody
品牌：
艾普蒂
产地：
武汉
保存条件：
Stored at -20°C for 3126 year. Avoid repeated freeze / thaw cycles.
产品类别：
抗体
重组：
否
应用：
WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性：
Human,Mouse,Rat
宿主：
Rabbit
偶联物：
无
靶点：
IL7

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/30-1/150 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM咨询技术 Human,Mouse,Rat
Elisa1/5000-1/10000 Human,Mouse,Rat
   

产品详情

AliasesIL-7
WB Predicted band size20 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse
ImmunogenSynthetic peptide of human IL7
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human kidney tissue and Mouse kidney tissue lysates, Primary antibody: P06447(IL7 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 7 minutes    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P06447(IL7 Antibody) at dilution 1/25. (Original magnification: ×200)    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P06447(IL7 Antibody) at dilution 1/25. (Original magnification: ×200)    


           

参考文献

以下是3-4篇关于IL7抗体的代表性文献概览(信息为模拟示例，实际文献需根据具体数据库查询)：

---

1. **文献名称**: *"Anti-IL-7 receptor α monoclonal antibody suppresses chronic inflammation in autoimmune diseases"*

**作者**: Smith A, et al. (2017)

**摘要**: 研究证明抗IL-7Rα单抗通过阻断IL-7信号通路，抑制T细胞过度活化，显著缓解类风湿性关节炎和多发性硬化症小鼠模型的炎症反应，提示其治疗自身免疫疾病的潜力。

---

2. **文献名称**: *"IL-7 neutralization ameliorates graft-versus-host disease by reducing T cell proliferation"*

**作者**: Chen L, et al. (2020)

**摘要**: 在小鼠异体造血干细胞移植模型中，中和IL-7的抗体通过抑制供体T细胞扩增，降低移植物抗宿主病(GVHD)严重程度，同时保留抗肿瘤免疫反应。

---

3. **文献名称**: *"Targeting IL-7 in cancer immunotherapy: Preclinical evaluation of a humanized anti-IL-7 antibody"*

**作者**: Kim J, et al. (2019)

**摘要**: 人源化抗IL-7抗体可阻断IL-7介导的肿瘤微环境中Treg细胞存活，增强CD8+ T细胞抗肿瘤活性，在结肠癌和黑色素瘤动物模型中表现出协同化疗的效果。

---

4. **文献名称**: *"IL-7 blockade restores lymphocyte homeostasis in HIV-infected patients"*

**作者**: Pérez L, et al. (2021)

**摘要**: 临床前研究表明，针对IL-7的单抗可调节HIV感染者异常的T细胞稳态，减少过度激活的CD4+ T细胞凋亡，为免疫重建提供新策略。

---

注：以上文献信息为示例，实际引用需通过PubMed、Web of Science等平台核实具体作者、年份及摘要内容。

       

背景信息

**Background of IL-7 Antibodies**

Interleukin-7 (IL-7) is a cytokine critical for lymphocyte development, homeostasis, and immune response regulation. It binds to the IL-7 receptor (IL-7R), composed of the IL-7Rα chain (CD127) and the common γ-chain (γc), activating downstream signaling pathways (JAK-STAT, PI3K-AKT, MAPK) that promote T-cell survival, proliferation, and differentiation. Dysregulated IL-7 signaling is implicated in autoimmune diseases, lymphopenia, and cancers, making it a therapeutic target.

IL-7 antibodies are engineered to either block or modulate IL-7/IL-7R interactions. Antagonistic antibodies inhibit IL-7 signaling, potentially treating autoimmune conditions (e.g., multiple sclerosis, rheumatoid arthritis) or preventing graft-versus-host disease. Conversely, agonistic antibodies may enhance IL-7 activity to boost T-cell reconstitution in immunodeficiency (e.g., post-chemotherapy or HIV) or improve antitumor immunity.

Clinical development faces challenges, including balancing efficacy with off-target effects and avoiding cytokine release syndrome. Novel strategies include bispecific antibodies targeting IL-7R and tumor antigens, or combining IL-7 antibodies with checkpoint inhibitors. Research also explores biomarkers (e.g., soluble IL-7R levels) to predict therapeutic response.

Despite preclinical promise, few IL-7 antibodies have reached late-stage trials, underscoring the need for refined targeting approaches. Ongoing studies aim to optimize antibody specificity, half-life, and safety profiles for diverse immunotherapeutic applications.

       
IL7抗体;IL7;IL7 Antibody;

公司简介

是一家科研、开发、生产和销售为一体的科技型企业，

成立日期 (2年)
注册资本 20万人民币
员工人数 1-10人
年营业额 ￥ 100万以内
经营模式 贸易,工厂,试剂,定制,服务
主营行业 抗体,蛋白组学,细胞生物学

IL7抗体相关厂家报价

内容声明
official 进入官方账号
拨打电话 立即询价